DoH Policies screened during the period: 1 April 2018 - 30 June 2018
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Technology Appraisal TA509 - Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
- NICE Technology Appraisal TA511 - Brodalumab for treating moderate to severe plaque psoriasis
- NICE Technology Appraisal TA513 - Obinutuzumab for untreated advanced follicular lymphoma
- NICE Technology Appraisal TA512 - Tivozanib for treating advanced renal cell carcinoma
- NICE Technology Appraisal TA514 - Regorafenib for previously treated advanced hepatocellular carcinoma
- NICE Technology Appraisal TA515 - Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (review of TA250)
- NICE Technology Appraisal TA516 - Cabozantinib for treating medullary thyroid cancer
- NICE Clinical Guideline NG82 - Age-related macular degeneration
- NICE Public Health Guideline NG63 - Antimicrobial stewardship: changing risk-related behaviours in the general population
- NICE Clinical Guideline NG85 - Pancreatic cancer in adults: diagnosis and management
- NICE Technology Appraisal TA517 - Avelumab for treating metastatic Merkel cell carcinoma
- NICE Technology Appraisal TA518 - Tocilizumab for treating giant cell arteritis
- NICE Clinical Guideline NG87 - Attention deficit hyperactivity disorder: diagnosis and management (updates & replaces CG72 & TA98)
- NICE Technology Appraisal TA520 - Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
- NICE Clinical Guideline NG88 - Heavy menstrual bleeding: assessment and management
- NICE Clinical Guideline NG89 - Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (updates & replaces CG92)
- NICE Clinical Guideline NG95 - Lyme disease
- The Regional Co-Production Guide